Nitrogen Attached Directly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 514/352)
  • Patent number: 11401231
    Abstract: This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 2, 2022
    Assignee: OZCHELA INC.
    Inventors: Min-Kyung Lee, Jin-Kak Lee, Won-Seok Han
  • Patent number: 11369593
    Abstract: The present invention includes compositions and methods for treating a subject afflicted with a neurodegenerative disorder or disease by determining that the subject is in need of treatment for the neurodegenerative disorder or disease; and administering to the subject an amount of an effective amount of a compound comprising a flupirtine derivative as disclosed herein.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 28, 2022
    Assignee: Texas Tech University System
    Inventors: Paul Trippier, Nihar Kinarivala, Rose-Mary Boustany
  • Patent number: 11351146
    Abstract: The present invention relates to a composition comprising a combination of a (halogenoacetamido)benzoate, a flavonol and a terpene, and, as example, relates to a composition comprising the combination of ethyl 3-(2-chloroacetamido)benzoate, dihydroquercetin and bisabolol. Said composition is for use in the treatment of leishmaniasis, especially cutaneous or mucosal leishmaniasis, the composition being applied topically for concomitantly treating both parasitic infection and skin inflammation of the infected area induced by leishmaniasis.
    Type: Grant
    Filed: September 3, 2018
    Date of Patent: June 7, 2022
    Inventors: Christian Auclair, Esther Fellous, Patrice Le Pape, Jorge E. Kalil-Filho
  • Patent number: 11225475
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 18, 2022
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11220484
    Abstract: An economic, one-step method for the production of N-substituted aromatic hydroxylamines of formula (I) R—N(OH)—C(?O)—(O)R1??(I), with hydrogen, by catalytic hydration with possibly modified hydration catalysts in an aprotic solvent and in the presence of a halogen formic acid ester and in some cases in the presence of a base.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: January 11, 2022
    Assignee: SOLVIAS AG
    Inventor: Heinz Steiner
  • Patent number: 10961236
    Abstract: Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: March 30, 2021
    Assignee: AstraZeneca AB
    Inventors: Matthew Perry, Christian Tyrchan, Konstantinos Karabelas, Antonios Nikitidis, Mickael Mogemark, Jens Petersen, Peter Bold, Ulf Borjesson
  • Patent number: 10799469
    Abstract: The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: October 13, 2020
    Assignee: TopoTarget UK Limited
    Inventors: Henri Lichenstein, Mike Jeffers, Xiaozhang Qian, Maxwell Sehested, Kamille Dumong Erichsen, James Ritchie
  • Patent number: 10561115
    Abstract: The present disclosure relates to propiconazole resistant mutants of Chlorella sp. having Accession No. CCAP 211/133. The propiconazole resistant mutants of Chlorella species have increased tolerance to propiconazole. The present disclosure further provides a method for preparing the propiconazole resistant mutants of Chlorella species. The propiconazole resistant mutants of Chlorella species can selectively grow in the presence of propiconazole, and hence can be used for large scale production of algal biomass.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 18, 2020
    Assignee: RELIANCE INDUSTRIES LIMITED
    Inventors: Chitranshu Kumar, Niraja Soni, Badrish Ranjitlal Soni, Gautam Das, Santanu Dasgupta
  • Patent number: 10426760
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 1, 2019
    Assignee: Plexxikon Inc.
    Inventors: Guoxian Wu, Jiazhong Zhang, Yong-Liang Zhu, Chao Zhang, Prabha N. Ibrahim, Songyuan Shi, Wayne Spevak, Dean R. Artis, James Tsai
  • Patent number: 10266523
    Abstract: The present disclosure relates to novel crystalline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl-4?-(trifluoromethoxy) [1,1?-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 23, 2019
    Assignee: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua Chen, Yanfeng Zhang, Fei Lu, Xiaoyu Zhang
  • Patent number: 10201545
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: February 12, 2019
    Assignee: ACUCELA INC.
    Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Anna Gall, Mark W. Orme, Jennifer Gage, Thomas L. Little, Jr., Qin Jiang, Lana Michele Rossiter, Kevin F. McGee, Jr., Ryo Kubota
  • Patent number: 10155750
    Abstract: The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 18, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Patent number: 9993429
    Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 12, 2018
    Assignee: University of Rochester
    Inventors: John Elfar, Kuang-Ching Tseng, Mark Noble
  • Patent number: 9856211
    Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: January 2, 2018
    Assignee: Topotarget UK Limited
    Inventors: Richard J. Bastin, Nicholas J. Hughes
  • Patent number: 9815846
    Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi-Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Kerim Babaoglu, Dongfang Meng, Jane Wu, Ping Liu, Harold B. Wood, Jianming Bao, Chun Sing Li, Qinghua Mao, Zhiqi Qi
  • Patent number: 9782394
    Abstract: Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: October 10, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Clifton Dalgard, Ahmed Mohamed, Meera Srivastava, Shiv Srivastava
  • Patent number: 9765050
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: September 19, 2017
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Ryan C. Clark, Yen Truong, Nicholas Stock, Jason Jacintho
  • Patent number: 9694025
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: July 4, 2017
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • Patent number: 9682065
    Abstract: An agent for treating heart failure, which improves left ventricular diastolic function itself without depending on the diuretic effect or vasodilation effect; controls the pathological condition of diastolic functional failure; and prevents the recurrence, and can prevent dyspnea and death from the pathological condition, is provided. By directly acting on a heart, 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid improves left ventricular diastolic function, and can effectively treat diastolic functional failure among heart failure types. Accordingly, by present invention, a new agent for treating heart failure that can relieve diastolic functional failure, for which no effective therapeutic method has been established, can be provided.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: June 20, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshiya Kanaji, Kazuhiro Fuchibe, Masaya Takahashi
  • Patent number: 9522884
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carbonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 20, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9452120
    Abstract: N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides of formula (1) are described that are potent modulators (e.g., inhibitors) of an androgen receptor, and which are useful, for example, in the treatment of a dermatological disease or disorder; a disease or disorder of the sebaceous gland(s); acne; hyperseborrhoea; oily skin, seborrhoeic dermatitis; hyperpilosity or hirsutism; atopic dermatitis; or androgenic alopecia; especially acne. Also described, are compositions (e.g., pharmaceutical compositions, cosmetic compositions) comprising the compounds; methods of preparing the compositions; methods of modulating (e.g., inhibiting) and androgen receptors using the compounds and/or compositions; and medical and/or cosmetic use of the compounds and compositions.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: September 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Cédric Poinsard
  • Patent number: 9376418
    Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 28, 2016
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Andrew M. Haidle, Sandra Lee Knowles, Solomon D. Kattar, Denis Deschenes, Jason Burch, Joel Robichaud, Matthew Christopher, Michael D. Altman, James P. Jewell, Alan B. Northrup, Marc Blouin, John Michael Ellis, Hua Zhou, Christian Fischer, Adam J. Schell, Michael H. Reutershan, Brandon M. Taoka, Anthony Donofrio
  • Patent number: 9340492
    Abstract: Meta-diarylaniline or meta-diarylpyridinamine compounds, methods for preparing the same and uses thereof in manufacture of a medicament. The compounds according to the present application have strong inhibitory activity (at nM level) against wild-type and various drug-resistant HIV viral strains, exhibit good druggability, and can be easily synthesized.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 17, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Lan Xie, Chin-Ho Chen, Lianqi Sun, Na Liu
  • Patent number: 9296694
    Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: March 29, 2016
    Assignee: ACADIA PHARMACEUTICALS INC.
    Inventors: Carl-Magnus A. Andersson, Glenn Croston, Eva Louise Hansen, Allan Kjaersgaard Uldam
  • Patent number: 9249122
    Abstract: 3-(3-Chloro-1H-pyrazol-1-yl)pyridine is prepared by cyclizing 3-hydrazinopyridine•dihydrochloride with acrylonitrile to provide 1-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-3-amine, by oxidizing to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine, and by converting the amino group to a chloro group by a Sandmeyer reaction.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: February 2, 2016
    Inventors: Qiang Yang, Beth Lorsbach, Xiaoyong Li, Gary Roth, David E. Podhorez
  • Patent number: 9199964
    Abstract: 3-(3-Chloro-1H-pyrazol-1-yl)pyridine is prepared by cyclizing 3-hydrazinopyridine.dihydrochloride with acrylonitrile to provide 1-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-3-amine, by oxidizing to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine, and by converting the amino group to a chloro group by a Sandmeyer reaction.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: December 1, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: Qiang Yang, Beth Lorsbach, Xiaoyong Li, Gary Roth, David E. Podhorez
  • Patent number: 9181238
    Abstract: The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R2, R3, R4 and R5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Shifeng Pan, John E. Tellew, Yongqin Wan, Yongping Xie, Xing Wang, Xia Wang, Shenlin Huang, Zuosheng Liu, Qiong Zhang
  • Patent number: 9145365
    Abstract: The present invention relates to an improved process for the preparation of Roflumilast. The present invention also relates to crystalline Form-I of Roflumilast.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: September 29, 2015
    Assignee: Mylan Laboratories Ltd.
    Inventors: Priyesh Vijaykar, Dattatrey Kokane, Sushant Gharat, Dhananjay Shinde, Manojkumar Bindu, Vinayak Gore
  • Patent number: 9084420
    Abstract: A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(=G1)-Q1 (wherein G1 and G2 represent an oxygen atom or the like, Q1 represents a phenyl group which may have a substituent, a heterocyclic group which may have a substituent, or the like), or the like, Q2 represents a phenyl group or the like, G3 represents an oxygen atom or the like, and R1 and R2 each independently represent a hydrogen atom, a C1-C6 alkyl group, or a group represented by -L-D, or the like (provided that at least either R1 or R2 represents a group represented by -L-D); as an active ingredient exhibits an excellent effect.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: July 21, 2015
    Assignee: Mitsui Chemicals Agro, Inc.
    Inventors: Yumi Kobayashi, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Hidenori Daido, Yusuke Takahashi, Shinichi Banba
  • Patent number: 9073866
    Abstract: Specific amine derivatives have been found to possess excellent activities as pest control agents.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: July 7, 2015
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Shinzo Kagabu, Masaaki Mitomi, Shigeki Kitsuda, Ryo Horikoshi, Masahiro Nomura, Yasumichi Onozaki
  • Patent number: 9056074
    Abstract: A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4?-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#1 and 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I and (ii) 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II are also disclosed.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: June 16, 2015
    Assignee: Sami Labs Limited
    Inventors: Krishnamani Jayaraman, Muhammed Majeed, Jeffrey Reinhardt, Kalyanam Nagabhushanam, Samuel Manoharan Thomas
  • Patent number: 9056834
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 16, 2015
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • Patent number: 9040530
    Abstract: Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 26, 2015
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Zhaozhong J. Jia, Brian Kane, Jack Rose, Shawn M. Bauer, Yonghong Song, Qing Xu, Anjali Pandey
  • Publication number: 20150141469
    Abstract: A kit for the production of an antimicrobial foam includes: a) a liquid composition which includes a1)one or more bispyridinium alkane and a2)one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and cation-active surfactants, wherein the composition is formulated so that a foam can be produced therefrom, and b) a device for producing the foam from the composition. By using the bispyridinium alkanes the foam stability of liquid and surfactant-containing compositions is increased.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Applicant: L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORG
    Inventors: Petra KOLDITZ, Sabine BEHRENDS, Anja BEHRENDT, Andreas DETTMANN, Thomas SPUIDA
  • Patent number: 9028855
    Abstract: The present invention pertains to plant additives containing a molecule selected in a family of compounds, wherein said molecule can modulate some molecular markers and physiological modifications observed in cases of phosphate deficiency. The family of compounds comprises the molecule MC2 of formula as well as analogs thereof.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 12, 2015
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Mathilde Clement, Thierry Desnos, Laurent Nussaume
  • Publication number: 20150126527
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 7, 2015
    Inventors: Thuy-Anh Tran, Weichao Chen, Bryan A. Kramer, Abu J.M. Sadeque, Anna Shifrina, Young-Jun Shin, Pureza Vallar, Ning Zou
  • Publication number: 20150119397
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Publication number: 20150119362
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 30, 2015
    Inventors: Mark E. Gurney, Timothy J. Hagen, Joel R. Walker, Xuesheng Mo, A. Samuel Vellekoop, Robert Campbell, Lei Zhu, Donna L. Romero
  • Publication number: 20150119426
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 30, 2015
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • Publication number: 20150111930
    Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.
    Type: Application
    Filed: October 23, 2013
    Publication date: April 23, 2015
    Applicant: AFGIN PHARMA, LLC
    Inventor: Ronald Aung-Din
  • Publication number: 20150105433
    Abstract: Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent that reduces ribosomal protein (Rps25) expression or function. Also provided are methods of inhibiting or promoting ribosomal shunting-mediated translation or non-IRES mediated translation. Also provided are methods of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 16, 2015
    Inventor: Sunnie R. Thompson
  • Patent number: 9006272
    Abstract: Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines, including bovine respiratory disease, are also disclosed.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 14, 2015
    Assignee: Intervet Inc.
    Inventors: Cheyney Meadows, Keith A. Freehauf, Robert D. Simmons, Allan J. Weingarten
  • Publication number: 20150099758
    Abstract: The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of al nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on al nAChRs in a mammal by administering an effective amount of a compound of Formula I.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 9, 2015
    Applicant: Anvyl LLC
    Inventors: David Putnam, Olivier Dasse
  • Publication number: 20150094338
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Applicant: PFIZER INC.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • Publication number: 20150094307
    Abstract: Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 2, 2015
    Inventors: Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
  • Publication number: 20150087517
    Abstract: The present disclosure relates to the manufacturing of specifically targeting microcapsules comprising agrochemicals. More specifically, the disclosure relates to specifically targeting microcapsules, to which targeting agents are covalently linked at a ratio from about 0.01 ?g-to about 1 ?g targeting agents per square centimeter of the surface of the microcapsule, such that the microcapsules are capable of binding the agrochemicals contained in the microcapsules to a surface, and to agrochemical compositions comprising such microcapsules.
    Type: Application
    Filed: October 8, 2012
    Publication date: March 26, 2015
    Inventors: Peter Verheesen, Chris De Jonghe
  • Patent number: 8987307
    Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: March 24, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Prabha Saba Karnachi, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer
  • Publication number: 20150080436
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: November 3, 2014
    Publication date: March 19, 2015
    Inventors: Andrew R. Blight, Ron Cohen
  • Publication number: 20150079116
    Abstract: NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 19, 2015
    Inventors: Jonathan Braun, Lin Lin
  • Patent number: RE47740
    Abstract: There is disclosed aminopyridine- and aminopyrimidinecarboxamide aminopyridinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides aminopyridinecarboxamide compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: November 26, 2019
    Assignee: Syntrix Biosystems Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler